Objective To systematicly evaluate SGLT2 inhibitors in the treatment of heart failure.Methods A systematic search on randomized controlled trial data in CNKI, Wanfang databases, Weipu journal resources databases, CBM, Pubmed, Cochrane Library, Embase, was performed. Two reviewers extracted data independently, and used Reviewer Manager Software(RevMan5.3)for statistical analysis.Results Eight studies (5 English papers, 3 Chinese papers)with 9264 patients were included in the systematic review. Clinical efficacy analysis showed that hospitalization rate for heart failure［OR=0.68，95％CI（0.60-0.77），Z=6.02，P＜0.00001］;all-cause mortality［OR=0.85，95％CI（0.75-0.97），Z=2.51，P=0.01］;Composite index( hospitalization rate for heart failure or cardiovascular mortality)［OR=0.77，95％CI（0.69-0.86），Z=4.84，P＜0.00001］; left ventricular ejection fraction［MD=-2.26，95％CI（-3.80，-0.71），Z=2.86，P=0.004］.〖WTHZ〗Conclusion SGLT2 inhibitors can significantly reduce the all-cause mortality of patients with heart failure, reduce the hospitalization risk and cardiovascular death events due to heart failure, and improve left ventricular ejection fraction. However, the number of included research literature is limited, and the total sample size of each study is large. Therefore, more clinical studies and real world data are needed to verify this result.